A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis
Phase of Trial: Phase III
Latest Information Update: 20 Nov 2016
At a glance
- Drugs HMPL 004 (Primary) ; Mesalazine
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms NATRUL-3
- Sponsors Hutchison MediPharma; Nutrition Science Partners
- 04 May 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
- 02 Nov 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2013-002116-27).
- 23 Oct 2013 New source identified and integrated (Oregon Health and Science University; IRB00009839).